Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
No Placebo
Drugs
Locations
Clinical Specialty
381-400 of 2,251 trials

Chemotherapy-Induced Peripheral Neuropathy: Capsaicin Patch vs. Duloxetine

We are studying whether a capsaicin patch can reduce nerve pain better than duloxetine in patients with chemotherapy-induced peripheral neuropathy. The trial also looks at safety and overall quality of life improvements.

Chemotherapy Induced Peripheral Neuropathy>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesNeurologyOncology

Severe Brain Injury: Apomorphine Treatment Study

We are investigating whether apomorphine can help patients with disorders of consciousness. The study also aims to identify which patients may respond best to this treatment.

Severe Brain Injury and Disorder of Consciousness≤3 monthsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesPartially RemoteNeurology

Advanced Tumors: TILs Treatment Study

We are studying a new therapy using tumor-infiltrating lymphocytes for patients with advanced tumors that have specific genetic changes. The goal is to see if this treatment can improve survival and tumor response.

Malignant Solid TumorEfficacy phase (II)No PlaceboInvestigational MedicinesOncology

Antithrombotic Therapy After Aortic Valve Implantation

We are studying whether a personalized, CT-guided antithrombotic therapy can better reduce serious heart and bleeding events compared to standard treatment in patients after transcatheter aortic valve implantation.

Aortic Valve StenosisMonitoring phase (IV)No PlaceboInvestigational MedicinesCardiologyInternal Medicine

Chronic Lymphocytic Leukemia: Zanubrutinib and Obinutuzumab Study

We are studying a combination of zanubrutinib and obinutuzumab for patients with untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma. The trial aims to see if this treatment helps achieve better remission rates compared to different schedules of drug administration.

Chronic Lymphocytic Leukemia (CLL)3-6 monthsEfficacy phase (II)No PlaceboStandard MedicinesHematologyOncology

Richter Transformation: Testing New Combination Therapy

We are studying a combination of three medications for patients with Richter transformation of chronic lymphocytic leukemia. The goal is to evaluate how well this treatment works and its safety.

Chronic Lymphocytic Leukaemia Variants>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesHematologyOncology

Vitamin D Deficiency: Cholecalciferol Study for Postmenopausal Women

We are investigating the right dose of Cholecalciferol to help postmenopausal women with vitamin D deficiency. The study also looks at how satisfied participants are with this vitamin D supplement.

Postmenopausal Women6-12 monthsConfirmation phase (III)No PlaceboStandard MedicinesEndocrinologyGynecology and Obstetrics

Small Cell Lung Cancer: Etoposide-Free Chemotherapy with Durvalumab

We are studying a new treatment combining chemotherapy and durvalumab for patients with extensive stage small cell lung cancer. The trial aims to see how well this treatment works and how it affects patients' quality of life.

Extensive Stage Small Cell Lung Cancer3-6 monthsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesOncology

Inotuzumab Ozogamicin for Pediatric Acute Lymphoblastic Leukemia

We are studying a new treatment for children with relapsed or refractory Acute Lymphoblastic Leukemia to see how well it works and how safe it is. This trial includes both single-agent and combination therapy approaches.

Recurrent Pediatric Acute Lymphoblastic LeukemiaSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHematologyPediatrics

Prostate Cancer: Estradiol and Exercise Study

We are exploring whether transdermal estradiol and resistance training can help reduce side effects like sexual dysfunction in men undergoing androgen deprivation therapy for prostate cancer. The study also looks at safety and quality of life improvements.

Prostate Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesEndocrinologyUrology

Atopic Dermatitis in Children: Upadacitinib vs. Dupilumab

We are studying whether upadacitinib is as safe and effective as dupilumab for children aged 2 to under 12 with moderate to severe atopic dermatitis. This trial aims to find better treatment options for young patients.

Atopic Dermatitis>2 yearsConfirmation phase (III)>20 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteAllergologyDermatologyPediatrics

HER2-Expressing Tumors: Trastuzumab Deruxtecan Study

We are studying the safety and effectiveness of Trastuzumab Deruxtecan in patients with advanced HER2-expressing tumors. This research aims to provide insights into new treatment possibilities for these patients.

HER2 Expressing Tumors6-12 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Cushing’s Disease: Lu AG13909 Treatment Study

We are investigating a new medication, Lu AG13909, for adults with Cushing’s disease to see how it affects cortisol levels and its safety. This trial aims to improve understanding of this rare condition and its treatment options.

Cushing's Disease1-2 yearsEfficacy phase (II)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteEndocrinologyInternal Medicine

New Surgical Treatment for Wet AMD: Vitrectomy and TPA

We are studying a new surgical approach for people with submacular hemorrhage caused by wet AMD. This trial compares it to the standard treatment to see if it improves vision and eye health.

Exudative Age-Related Macular Degeneration1-2 yearsConfirmation phase (III)No PlaceboStandard MedicinesOphthalmology

Bronchiectasis: Comparing Antibiotic Treatments for PA Infection

We are studying two antibiotic regimens to see which is more effective for adults with bronchiectasis and early Pseudomonas aeruginosa infections. This research may help improve treatment options for these patients.

Bronchiectasis>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesInfectious DiseasesPulmonology

Recurrent Pericarditis in Children: Anakinra vs. Steroids

We are studying whether Anakinra is more effective than steroids for controlling recurrent pericarditis in children who haven't responded to other treatments. This trial aims to help improve care for young patients facing this condition.

Pericarditis3-6 monthsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesCardiologyRheumatology

Chronic Open-Angle Glaucoma: Preservative-Free Bimatoprost Eye Drops

We are comparing a new preservative-free eye drop to a standard treatment for patients with chronic open-angle glaucoma or ocular hypertension. The goal is to see if the new formulation is effective and safe for managing eye pressure.

Chronic Open-angle GlaucomaOcular Hypertension3-6 monthsConfirmation phase (III)No PlaceboStandard MedicinesOphthalmology

Chronic Pouchitis in Children: Vedolizumab IV Study

We are testing the intravenous medication vedolizumab in children with active chronic pouchitis to see if it helps them achieve remission. The study will also look at how well the treatment is tolerated and its overall effectiveness.

Pouchitis1-2 yearsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementGastroenterologyPediatrics

Cystic Fibrosis: VX-522 Treatment Study

We are testing a new medication, VX-522, for adults with cystic fibrosis who do not respond to current treatments. The study will help us understand its safety and effectiveness compared to existing therapies.

Cystic Fibrosis6-12 monthsSafety phase (I)Efficacy phase (II)>20 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPulmonology

Epcoritamab for Relapsed/Refractory Chronic Lymphocytic Leukemia

We are studying a new treatment called epcoritamab for patients with relapsed or refractory chronic lymphocytic leukemia and Richter's syndrome. The goal is to assess its safety and effectiveness, both alone and with other medications.

Chronic Lymphocytic Leukemia>2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementOncology